Helena Nissinen - Concepedia

Author

Helena Nissinen

Orion Corporation (Finland)

Also Known As

H Nissinen, H. Nissinen, Helena Nissinen

Publications

635

Citations

H-Index

Concepts

All Affiliations

Orion Corporation (Finland)Kista Photonics Research Center University of Turku The Royal Free Hospital National Hospital for Neurology and Neurosurgery

About

Helena Nissinen is an author at Orion Corporation (Finland) specializing in medicine, movement disorders, and pharmacotherapy.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	4	4	558
2	Neurology	2	2	488
3	Health Sciences	1	1	455
4	Endocrinology	1	1	40
5	Kinesiology	1	1	455

Helena Nissinen

Publications

635

Citations

H-Index

Page 1

	Year	Citations
Factors predictive of the development of Levodopa‐induced dyskinesia and wearing‐off in Parkinson's disease C. Warren Olanow, Karl Kieburtz, Olivier Rascol, Movement Disorders KinesiologyHealth SciencesParkinson DiseaseL-dopa DoseClinical Trials	2013	455
Burden of illness in multiple sclerosis (DEFENSE) study: the costs and quality-of-life of Finnish patients with multiple sclerosis Juhani Ruutiainen, Anna-Mari Viita, Jarmo Hahl, Journal of Medical Economics	2015	45
The COMT inhibitor, entacapone, reduces levodopa-induced elevations in plasma homocysteine in healthy adult rats Erkki Nissinen, Helena Nissinen, H. Larjonmaa, Journal of Neural Transmission Plasma HomocysteineMedicineLevodopa-induced ElevationsPhysiologyComt Inhibitor	2004	40
Five-year efficacy and safety of levodopa/DDCI and entacapone in patients with Parkinson’s disease David J. Brooks, Mika Leinonen, Mikko Kuoppamäki, Journal of Neural Transmission Neurodegenerative DiseasesMedicineParkinson DiseaseClinical TrialsParkinson ’	2008	33
Early versus delayed initiation of entacapone in levodopa‐treated patients with Parkinson’s disease: a long‐term, retrospective analysis Helena Nissinen, Mikko Kuoppamäki, M. Leinonen, European Journal of Neurology	2009	32
Direct switch from levodopa/benserazide or levodopa/carbidopa to levodopa/carbidopa/entacapone in Parkinson’s disease patients with wearing-off: efficacy, safety and feasibility—an open-label, 6-week study Karla Eggert, Örjan Skogar, Khaled Amar, Journal of Neural Transmission PharmacologyDirect SwitchNeuropharmacologyPharmacotherapy6-Week Study	2009	30

Page 1